Cargando…

Novel Potency Assay for MSC Secretome-Based Treatment of Idiopathic Male Infertility Employed Leydig Cells and Revealed Vascular Endothelial Growth Factor as a Promising Potency Marker

Idiopathic male infertility is a highly prevalent diagnosis in developed countries with no specific treatment options. Although empirical medical treatment is widely used to restore male fertility, its efficacy remains limited and inconclusively proven. Therefore, the development of novel therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Monakova, Anna, Sagaradze, Georgy, Basalova, Nataliya, Popov, Vladimir, Balabanyan, Vadim, Efimenko, Anastasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409465/
https://www.ncbi.nlm.nih.gov/pubmed/36012677
http://dx.doi.org/10.3390/ijms23169414
_version_ 1784774857976709120
author Monakova, Anna
Sagaradze, Georgy
Basalova, Nataliya
Popov, Vladimir
Balabanyan, Vadim
Efimenko, Anastasia
author_facet Monakova, Anna
Sagaradze, Georgy
Basalova, Nataliya
Popov, Vladimir
Balabanyan, Vadim
Efimenko, Anastasia
author_sort Monakova, Anna
collection PubMed
description Idiopathic male infertility is a highly prevalent diagnosis in developed countries with no specific treatment options. Although empirical medical treatment is widely used to restore male fertility, its efficacy remains limited and inconclusively proven. Therefore, the development of novel therapeutic approaches in this field is a high-priority task. Since the failure of testicular microenvironment components might be involved in the pathogenesis of idiopathic male infertility, application of mesenchymal stromal cells (MSCs) as well as the MSC secretome is worth considering. Previously, we showed that the intratesticular injection of MSCs or the MSC secretome led to the recovery of spermatogenesis at least through replenishing the testicular microenvironment and its maintenance by MSC-secreted paracrine factors. However, the clinical use of such products has been limited to single trials to date. This may be due to the lack of relevant potency tests reflecting mechanisms of action of the MSC secretome in male infertility models. Based on the presumptive MSC secretome mode of action on the testicular microenvironment, we suggest a novel approach to test the potential efficacy of the MSC secretome for idiopathic male infertility treatment. It represents a potency assay based on evaluation of testosterone production by isolated Leydig cells. We demonstrated that the MSC secretome stimulated testosterone secretion by Leydig cells in vitro. We then hypothesized that among the major factors of the MSC secretome, vascular endothelial growth factor (VEGF) could be responsible for the observed effects, which we confirmed by the revealed correlation between the extent of stimulated testosterone production and VEGF concentration in the MSC secretome. The pilot results obtained from the doxorubicin-induced male infertility murine model also indicate the important impact of VEGF in the MSC secretome’s regenerative effects. Utilizing VEGF as a surrogate factor, a novel approach to study the potency of MSC secretome-based products for idiopathic male infertility treatment is suggested. Further validation is required for its implementation into the biopharmaceutical manufacturing process.
format Online
Article
Text
id pubmed-9409465
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94094652022-08-26 Novel Potency Assay for MSC Secretome-Based Treatment of Idiopathic Male Infertility Employed Leydig Cells and Revealed Vascular Endothelial Growth Factor as a Promising Potency Marker Monakova, Anna Sagaradze, Georgy Basalova, Nataliya Popov, Vladimir Balabanyan, Vadim Efimenko, Anastasia Int J Mol Sci Article Idiopathic male infertility is a highly prevalent diagnosis in developed countries with no specific treatment options. Although empirical medical treatment is widely used to restore male fertility, its efficacy remains limited and inconclusively proven. Therefore, the development of novel therapeutic approaches in this field is a high-priority task. Since the failure of testicular microenvironment components might be involved in the pathogenesis of idiopathic male infertility, application of mesenchymal stromal cells (MSCs) as well as the MSC secretome is worth considering. Previously, we showed that the intratesticular injection of MSCs or the MSC secretome led to the recovery of spermatogenesis at least through replenishing the testicular microenvironment and its maintenance by MSC-secreted paracrine factors. However, the clinical use of such products has been limited to single trials to date. This may be due to the lack of relevant potency tests reflecting mechanisms of action of the MSC secretome in male infertility models. Based on the presumptive MSC secretome mode of action on the testicular microenvironment, we suggest a novel approach to test the potential efficacy of the MSC secretome for idiopathic male infertility treatment. It represents a potency assay based on evaluation of testosterone production by isolated Leydig cells. We demonstrated that the MSC secretome stimulated testosterone secretion by Leydig cells in vitro. We then hypothesized that among the major factors of the MSC secretome, vascular endothelial growth factor (VEGF) could be responsible for the observed effects, which we confirmed by the revealed correlation between the extent of stimulated testosterone production and VEGF concentration in the MSC secretome. The pilot results obtained from the doxorubicin-induced male infertility murine model also indicate the important impact of VEGF in the MSC secretome’s regenerative effects. Utilizing VEGF as a surrogate factor, a novel approach to study the potency of MSC secretome-based products for idiopathic male infertility treatment is suggested. Further validation is required for its implementation into the biopharmaceutical manufacturing process. MDPI 2022-08-20 /pmc/articles/PMC9409465/ /pubmed/36012677 http://dx.doi.org/10.3390/ijms23169414 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Monakova, Anna
Sagaradze, Georgy
Basalova, Nataliya
Popov, Vladimir
Balabanyan, Vadim
Efimenko, Anastasia
Novel Potency Assay for MSC Secretome-Based Treatment of Idiopathic Male Infertility Employed Leydig Cells and Revealed Vascular Endothelial Growth Factor as a Promising Potency Marker
title Novel Potency Assay for MSC Secretome-Based Treatment of Idiopathic Male Infertility Employed Leydig Cells and Revealed Vascular Endothelial Growth Factor as a Promising Potency Marker
title_full Novel Potency Assay for MSC Secretome-Based Treatment of Idiopathic Male Infertility Employed Leydig Cells and Revealed Vascular Endothelial Growth Factor as a Promising Potency Marker
title_fullStr Novel Potency Assay for MSC Secretome-Based Treatment of Idiopathic Male Infertility Employed Leydig Cells and Revealed Vascular Endothelial Growth Factor as a Promising Potency Marker
title_full_unstemmed Novel Potency Assay for MSC Secretome-Based Treatment of Idiopathic Male Infertility Employed Leydig Cells and Revealed Vascular Endothelial Growth Factor as a Promising Potency Marker
title_short Novel Potency Assay for MSC Secretome-Based Treatment of Idiopathic Male Infertility Employed Leydig Cells and Revealed Vascular Endothelial Growth Factor as a Promising Potency Marker
title_sort novel potency assay for msc secretome-based treatment of idiopathic male infertility employed leydig cells and revealed vascular endothelial growth factor as a promising potency marker
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409465/
https://www.ncbi.nlm.nih.gov/pubmed/36012677
http://dx.doi.org/10.3390/ijms23169414
work_keys_str_mv AT monakovaanna novelpotencyassayformscsecretomebasedtreatmentofidiopathicmaleinfertilityemployedleydigcellsandrevealedvascularendothelialgrowthfactorasapromisingpotencymarker
AT sagaradzegeorgy novelpotencyassayformscsecretomebasedtreatmentofidiopathicmaleinfertilityemployedleydigcellsandrevealedvascularendothelialgrowthfactorasapromisingpotencymarker
AT basalovanataliya novelpotencyassayformscsecretomebasedtreatmentofidiopathicmaleinfertilityemployedleydigcellsandrevealedvascularendothelialgrowthfactorasapromisingpotencymarker
AT popovvladimir novelpotencyassayformscsecretomebasedtreatmentofidiopathicmaleinfertilityemployedleydigcellsandrevealedvascularendothelialgrowthfactorasapromisingpotencymarker
AT balabanyanvadim novelpotencyassayformscsecretomebasedtreatmentofidiopathicmaleinfertilityemployedleydigcellsandrevealedvascularendothelialgrowthfactorasapromisingpotencymarker
AT efimenkoanastasia novelpotencyassayformscsecretomebasedtreatmentofidiopathicmaleinfertilityemployedleydigcellsandrevealedvascularendothelialgrowthfactorasapromisingpotencymarker